2023年9月1日 · The purpose of this phase I study was to primarily assess the safety of the CNTF-secreting NT-501 implant in patients with primary open-angle glaucoma and evaluate the effect of CNTF on retinal structure and visual function.

CNTF-Secreting Cells for Treatment of MacTel Neurotech Pharmaceuticals, with support from the Lowy Medical Research Institute, is testing the safety and efficacy of ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2 in a Phase 3 clinical trial.

2023年3月11日 · Purpose: To assess the safety and efficacy of a ciliary neurotrophic factor (CNTF) intraocular implant on neuroprotection and neuroenhancement in glaucoma. Design: Open-label, prospective, phase I clinical trial. Participants: A total of 11 participants were diagnosed with primary open-angle glaucoma (POAG).

2024年6月20日 · The implant leverages ciliary neurotrophic factor (CNTF), which is a neuroprotective protein that promotes not only the survival of photoreceptors, but also the maintenance of them. Targeted therapy slows retinal degeneration via sustained delivery of CNTF, resulting in improved long-term visual outcomes for patients.

2019年2月15日 · The FDA has fast-tracked Neurotech’s implant for stalling central vision loss in people with type 2 macular telangiectasia (MacTel). The device, Renexus, is a semipermeable fiber membrane filled with human retinal pigment epithelium cells …

Designed to be implanted into the vitreous cavity of the eye, the investigational NT-501implant is a tiny hollow cylindrical membrane which encapsulates human epithelial cells genetically engineered to produce ciliary neurotropic factor (CNTF) continuously, a protein now clinically validated in Phase 3 clinical trials to slow the progression of ...

2021年7月31日 · Data from a phase 2 study (NCT01949324) of the NT-501 implant containing ciliary neurotrophic factor (CNTF) suggest that the treatment is efficacious in slowing neurodegeneration in macular telangiectasia type 2. 1. An increase in the area of the ellipsoid zone loss was used to measure disease progression in patients with MacTel type 2.

2018年10月4日 · The well-designed, randomized Macular Telangiectasia Type 2-Phase 2 CNTF study provides evidence to support the use of objective measures of retinal structure as primary outcome measures for clinical trials.

NT-501 Slows Progression of Disease over 24 months (CNTF) has a beneficial effect in patients with Macular Telangiectasia type 2 (MacTel). The multicenter, randomized clinical trial demonstrated a statistically signific

To report the 18-month Phase 2 study results of an encapsulated CNTF-secreting cell implant in eyes with geographic atrophy associated with dry AMD. The CNTF study consists of 48 participants that were randomized in a 2:1:1 ratio to receive an intravitreal high or low CNTF output implant, or to sham surgery, respectively.